News|Articles|November 17, 2026

FDA Removes Limitations of Use for Liso-Cel in Primary Central Nervous System Lymphoma

Author(s)Chris Ryan
Fact checked by: Ashling Wahner
Listen
0:00 / 0:00

Key Takeaways

  • FDA labeling for liso-cel in LBCL no longer includes a limitation of use excluding patients with PCNSL.
  • The approved LBCL subtypes span DLBCL NOS (including transformed disease), high-grade B-cell lymphoma, PMBCL, and grade 3B follicular lymphoma.
SHOW MORE

The FDA approved a label update for axi-cel, removing its limitations of use for patients with primary central nervous system lymphoma.

The FDA has approved a label update for the indication for lisocabtagene maraleucel (Breyanzi; liso-cel) in large B-cell lymphoma (LBCL), removing the limitations of use for the CAR T-cell therapy in patients with primary central nervous system lymphoma (PCNSL).1

Liso-cel is approved for adult patients with LBCL, including diffuse LBCL (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who have:

  • refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or
  • refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age; or
  • relapsed or refractory disease after 2 or more lines of systemic therapy

Liso-cel is now the second CAR T-cell therapy to have its limitations of use removed for patients with PCNSL, following the FDA’s February 2026 approval of a label update for axicabtagene ciloleucel (axi-cel; Yescarta; axi-cel).2

References

  1. Breyanzi. Prescribing information. Updated November 2026. Accessed November 17, 2026. https://packageinserts.bms.com/pi/pi_breyanzi.pdf
  2. FDA approves label update for Kite’s Yescarta for relapsed/refractory primary central nervous system lymphoma. News release. Kite. February 06, 2026. Accessed November 17, 2026. https://www.kitepharma.com/news/press-releases/2026/2/fda-approves-label-update-for-kites-yescarta-for-relapsedrefractory-primary-central-nervous-system-lymphoma

Related to this article